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Abstract
The occurrence of Serious Adverse Experiences (SAEs) following Mectizan® treatment of onchocerciasis
in Loa loa endemic areas has been increasingly reported over the past decade. These SAEs include a
severely disabling, and potentially fatal, encephalopathy, which appears to correlate with a high load of L.
loa microfilariae (> 30,000 mf/ml).
Previous consultations organized by the Mectizan® Donation Program (MDP) in 1995 and 1999 have
developed useful "case" definitions of encephalopathic SAEs following Mectizan® treatment and have
summarized available evidence on its pathogenesis and optimal clinical management. At both meetings, the
need for better understanding of the pathogenesis of the encephalopathy was emphasized, including the
need for biological and autopsy specimens from the affected cases.
Following a recommendation at the Joint Action Forum of the African Programme for Onchocerciasis
Control in December 2001, the MDP, on behalf of the Mectizan® Expert Committee, organized a Scientific
Working Group on L. loa associated SAEs following Mectizan® treatment in May 2002. The present report
includes the background, new evidence, conclusions and recommendations from that Scientific Working
Group. The following points represent a summary of the present status:
1. Although there are more and better quality clinical and epidemiological data on L. loa, the pathogenesis
of the Mectizan®-related L. loa encephalopathy remains obscure.
2. Very limited progress has been made in research on the pathogenesis of encephalopathy, because of the
lack of specimens from cases, and the lack of animal models.
3. There has been no particular breakthrough in terms of the medical management of patients with L. loa
encephalopathy; however, a favorable outcome usually results from prompt general nursing and nutritional
care which remain the major interventions.
The main recommendations for future actions are as follows:
1. Validate and update the mapping of L. loa with a combination of remote sensing and RAPLOA techniques.
2. Conduct an expert analysis of the apparent clustering of encephalopathic SAEs reported so far.
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3. Investigate a possible "pre-treatment" scheme with high-dose albendazole in L. loa endemic communities
at high risk of encephalopathic SAEs if treated with Mectizan®; this study will be conducted in collaboration
with WHO/TDR.
4. Establish a post of Loiasis Technical Advisor for research and operational support in Cameroon, to
conduct population surveys and to facilitate better data collection from SAE cases, including postmortem
studies as appropriate.
5. Investigate the possibility of developing an animal model of L. loa encephalopathy; this activity would be
linked to the above-mentioned research agenda in Cameroon.
6. Investigate the best care model for encephalopathic SAEs, including identification of early warning signs
and therapeutic interventions.
7. Develop further models for health education messages needed for community compliance with
Mectizan® treatment, and family support for SAE cases.
8. Conduct research studies on the safety of combination therapy of Mectizan® and albendazole in areas
co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that
oversee these issues.
The above recommendations will be implemented through a continuing collaboration between the
interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or
the Global Programme to Eliminate Lymphatic Filariasis.
Introduction
After a brief welcome of participants by Professor David
Molyneux and Dr Björn Thylefors, the meeting was
opened by the Chairman, Professor Mamoun Homeida.
The agenda (see Additional File 1) was adopted and par-
ticipants briefly introduced themselves (see Additional
File 2 for List of Participants). The terms of reference for
the meeting (see Additional File 3) were reviewed.
Review Of Previous Consultations On Loa Loa 
Associated SAEs – Björn Thylefors
The outcome of the two previous consultations convened
by the Mectizan® Donation Program (MDP) was briefly
reviewed. In the first meeting, which took place in Paris,
France in 1995 on the theme of "CNS Complications of
Loiasis and Adverse CNS Events following Treatment" a
case definition was worked out, which has since been use-
fully applied. These definitions allowed for the classifica-
tion of "definite" or "probable" Loa loa related cases, as
distinguished from "coma events" in L. loa endemic areas.
It was noted that the case definition in 1995 retained a
post-treatment microfilaremia of 1,000 mf/ml or more.
Today, available data would place this level between
3,000 – 5,000 mf/ml. More information and evidence is
available today in the field of epidemiology, including
new tools such as remote sensing mapping for L. loa and
the recently elaborated RAPLOA technique for commu-
nity assessment of high risk for Serious Adverse Experi-
ences (SAEs) following treatment with Mectizan®.
In contrast, there is still little progress being made in the
field of pathogenesis of the encephalopathy that typically
ensues in heavily infected loiasis cases treated with Mecti-
zan®. The persistent lack of biological specimens from
these cases is a particular obstacle to progress in this
regard. The reporting of SAEs also leaves much to be
desired; it is often delayed, incomplete and contains irrel-
evant information instead of focusing on the main clinical
and laboratory data needed. As a follow-up to the 1995
consultation, a survey on the SAE reporting system is now
being conducted by the MDP, with a view to improving
reporting performance.
The 1999 consultation, convened in Tours, France,
focused more on the clinical picture, and possible associ-
ated conditions. There were no formal recommendations
adopted at that meeting but suggestions were made to
heighten monitoring for the first round of Mectizan® treat-
ment in L. loa endemic areas and to refine the borders of
areas of meso- and hyper- endemic onchocerciasis ende-
micity in order to justify treatment of communities at risk
of SAEs. Stricter medical supervision was also proposed as
a means of reducing the risk of permanent sequelae of
SAEs following Mectizan® treatment in L. loa endemic
areas.
Overall, it was felt that the two previous consultations had
certainly been of use, but there was now a need to take
advantage of some new openings, such as easier assess-
ment of L. loa endemic areas, and to draw up an agenda
for needed research in the immediate and mid-term per-
spective. This aim was reflected in the terms of reference
for the present meeting (see Additional File 3).Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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Since working papers for the meeting had been previously
distributed to participants, it was intended that presenta-
tions would be brief, focusing only on salient points, in
order to facilitate maximum discussion and formulation
of recommendations. The list of working papers submit-
ted for the meeting is provided in Additional file 4.
Mapping Of L. Loa
Remote sensing – David Molyneux
Overview
A remote sensing map of L. loa has been developed by the
Liverpool School of Tropical Medicine (see Additional
File 5). Predicted prevalence was based on several envi-
ronmental factors suggestive of the presence of Chrysops
spp. while epidemiological surveys conducted by the Insti-
tut de Recherche pour le Développement (IRD) in Cam-
eroon from 1991 to 2001, provided the observed
prevalence data to determine the best predictive model.
Mapping of other parts of Central Africa, Sudan and Ethi-
opia are ongoing.
RAPLOA Validation – Hans Remme
Overview
A rapid epidemiological assessment of community preva-
lence of high intensity L. loa microfilaremia, based on a
simple questionnaire, has been developed by TDR and
conducted in Cross River State in south-eastern Nigeria,
and in the North West, South West and East provinces of
Cameroon. Prevalence was found to be highly correlated
with intensity of infection. The most sensitive and specific
survey question was that which was restricted to individu-
als who responded positively to a past experience of an
eye worm, confirmed by a representative photograph, and
which lasted between 1 and 7 days (RAPLOA). Validation
of the RAPLOA technique is ongoing. The sampling meth-
odology and the threshold at which 'high-risk' communi-
ties are identified are yet to be determined.
Recommendations
1. TDR and Liverpool to continue their collaboration to
validate these tools. Validation of remote sensing map-
ping should include predicted negative as well as pre-
dicted positive areas.
2. Develop a protocol to combine these tools for mapping
of L. loa that assesses both presence of infection and risk
of L. loa encephalopathy following treatment with Mecti-
zan®  (% of restricted eye worm defined as a proxy
indicator).
3. Consider different thresholds of RAPLOA positivity
before defining the threshold to be used in the field to
minimize the risk of L. loa encephalopathy following
treatment with Mectizan® in a given community.
Recent Advances In Knowledge About SAEs In L. 
Loa Endemic Areas
Review of reported cases – Nana Twum-Danso
Overview
1. The definitions of SAEs and important medical events
which may be considered SAEs were provided:
A serious adverse event/experience is "an adverse experi-
ence occurring at any dose that results in any of the fol-
lowing outcomes:
- Death
- Life-threatening adverse drug experience
- Hospitalization or prolongation of existing hospitalization
- Persistent or significant disability/incapacity
- Congenital anomaly/birth defect
- Cancer
- Overdose (accidental or intentional)
Other important medical events that may not result in
death, not be life threatening, or not require hospitaliza-
tion may be considered an SAE when,
based upon appropriate medical judgment, the event may
jeopardize the subject/patient and may require medical or
surgical intervention to prevent one of the outcomes listed
above" (Merck & Co., Inc.).
2. As of May 10, 2002 a total of 204 SAE cases have been
reported to the MDP as having occurred since the mass
treatment program began in 1988 up to the end of 2001,
giving rise to a cumulative incidence of approximately 1
reported SAE per 1 million treatments.
3. In light of research findings made available since the
1995 MDP consultation on L. loa encephalopathy, the
case definitions have been modified by the MDP (see
Additional File 6).
4. The majority of these SAE cases have been reported
from Cameroon (n = 175; 86%). Ninety-six of the 175
cases from Cameroon (55%) were encephalopathic in
nature; 61 had sufficient clinical and laboratory data to
support a diagnosis of 'Probable' or 'Possible' L. loa
Encephalopathy temporally Related to treatment with
Mectizan®  (PLERM) (see Additional File 6 for case
definitions).Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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5. There appears to be a clustering of PLERM cases in the
Central Province of Cameroon, from where 51 of the 61
PLERM cases have been reported. The neighboring dis-
tricts of Monatélé and Okola reported the highest number
(and highest incidence) of PLERM during the years 1994/
95 and 1999 respectively when mass treatment programs
were initially launched in those districts.
6. During 2001, there appears to have been over-reporting
of SAEs that are not clinically important but fit the strict
definition of an SAE, such as mild-Mazzotti reactions. The
use of hemorrhages of the palpebral conjunctivae (HPC)
as a screening tool for impending PLERM, though useful,
may be exacerbating this problem since it lacks specificity
and may be poorly differentiated by the community
health volunteers.
7. Interpretation of these data are limited due to the over-
all poor quality and incomplete nature of SAE forms
returned to the MDP and the lack of knowledge about
incidence of SAEs in countries other than Cameroon.
8. In order to better understand the epidemiology of
PLERM, the MDP is currently conducting a survey of
onchocerciasis field staff at the national and peripheral
health levels, to investigate the degree of under-reporting,
if any, from countries other than Cameroon.
Recommendations
1. Determine spatial distribution of the encephalopathic
cases at village level using GIS software to better under-
stand the clustering phenomenon observed.
2. In spite of the limitations of clinical data submitted,
determine case-fatality rates, trends over time, and effec-
tiveness of supportive treatment of PLERM cases.
3. Continue to monitor aggregate numbers. It is impor-
tant to include an assessment of number of cases per first-
round treatments.
4. Where possible, correlate encephalopathic cases with L.
loa aggregate mf (CMFL or RAPLOA results).
5. Accept modified case definitions of L. loa encephalopa-
thy.
Clinical picture, epidemiology & outcome – Michel 
Boussinesq
Overview
1. The most common symptoms reported by SAE patients
in L. loa endemic areas are fatigue, anorexia, headache,
generalized arthralgia and severe lumbar pain; onset of
symptoms is usually within the first 12–24 hours. For
patients who develop encephalopathy, the above-listed
symptoms are also associated with confusion, agitation,
dysarthria, aphasia and incontinence which may begin as
early as the first day following treatment with Mectizan®.
2. HPCs have been associated with pre-treatment L. loa
microfilaremia of > 1000 mf/ml and may serve as an early
screening tool, that could be easily applied at the village
level, even though it would yield a high false-positive rate.
3. Treatment with Mectizan® has been associated with pas-
sage of L. loa mf into the cerebrospinal fluid (CSF) irre-
spective of pre-treatment L. loa mf levels. However there
was an observed gradient in this phenomenon: a greater
proportion of individuals with levels > 30,000 mf/ml
compared to those with 15,000 to 30,000 mf/ml, and a
greater proportion of individuals with 15,000 to 30,000
mf/ml compared to those with < 15,000 mf/ml. Not all
individuals in whom this phenomenon was observed
developed an encephalopathy.
4. Treatment with Mectizan® has also been associated with
hematuria and microfilaruria, the level of which correlates
with the pre-treament L. loa microfilarial load.
5. Eosinophil levels have been shown to decrease dramat-
ically 24 hours after treatment with Mectizan®, and rise
above pre-treatment levels 48 hours later.
6. Electroencephalographic and computed tomography
studies have been of limited value in these cases, yielding
no clearly identified patterns.
7. Based on the work of Boussinesq and colleagues, the
single known risk factor for developing L. loa encephalop-
athy is pre-treatment L. loa microfilaremia > 50,000 mf/
ml. Age and gender have not been definitely shown to be
correlated with risk.
Recommendations
1. Additional work should be done to test the usefulness
of possible predictors of high-density microfilaremia, L.
loa  encephalopathy, and chronic neurologic sequelae,
including:
• Existence of local terminology for eye worm
• History of repeated eye worm passage on an individual
level; possible sources of data include the RAPLOA study
by TDR and unpublished studies conducted in
Cameroon.
2. The usefulness of HPC as a predictor of impending neu-
rologic involvement of L. loa associated adverse reactions
should be immediately studied to determine, among oth-
ers, whether this sign could be correctly recognized byFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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community-based distributors and health workers. If
these studies appear promising, the MDP or African Pro-
gramme for Onchocerciasis Control (APOC) should
sponsor the development of laminated cards depicting
HPCs and describing appropriate referral and manage-
ment of patients with this condition.
Immunopathology & immunogenetics – Charles 
Mackenzie
Overview
1. Clinical and laboratory findings suggest that Mectizan®-
associated L. loa encephalopathy:
• is consistent with an embolic process triggered by mas-
sive microfilarial death;
• may also involve circulating immune complexes or pol-
ymorphic inflammatory responses;
• differs from the acute neurologic reactions seen in some
animals (e.g., collie dogs) following treatment with Mec-
tizan®, which is associated with mutation of the multiple
drug resistance (mdr1) gene and inadequate production
of P glycoprotein.
2. Research on the pathogenesis and treatment of L. loa
encephalopathy has been inhibited by the lack of an ani-
mal model and the paucity of:
• detailed epidemiological and clinical information;
• diagnostic specimens during the course of illness; and
• autopsies and post-mortem tissue specimens.
Recommendations
1. Consideration should be given to the development of a
murine model of L. loa encephalopathy, preferably in an
area endemic for loiasis.
2. Although it would be costly and perhaps difficult to
obtain the necessary clearances, the feasibility of develop-
ing a primate model of L. loa encephalopathy should be
explored.
3. When cases of L. loa encephalopathy occur, attempts
should be made to collect and have tested:
• serial blood/serum specimens;
• conjunctival biopsies;
• tissue specimens on autopsy (e.g. via transphenoidal or
transethmoidal route).
4. A position for a "Loiasis Technical Advisor" should be
created and filled as soon as possible in Cameroon. The
Technical Advisor would work closely and liaise with the
Ministry of Health, the National Onchoceriasis Task Force
(NOTF), and other partners involved in onchocerciasis
control and lymphatic filariasis elimination, but would
retain a certain independence in that he/she would not
work "for" any one particular group. The responsibilities
of this position would include, among others:
a. Responding quickly when cases of L. loa encephalopa-
thy occur to collect detailed epidemiological and clinical
information on each case;
b. Collecting necessary laboratory and tissue specimens;
c. Assisting the NOTF and others with adhering to guide-
lines for Mectizan® treatment strategies in L. loa endemic
areas;
d. Assisting the NOTF and the Ministry of Health with epi-
demiological mapping and surveillance of L. loa, Wuchere-
ria bancrofti, and Onchocerca volvulus;
e. Conducting operational research on risk factors for, and
clinical management of, L. loa encephalopathy and its
sequelae;
f. Conducting formative research on attitudes and beliefs
regarding Loa encephalopathy;
g. Conducting ethnographic research on patterns of food
and beverage consumption and use of traditional medi-
cines that may increase risk of L. loa encephalopathy.
Pathogenic role of Wolbachia – Mark Taylor
Overview
The presentation provided a brief history of the events
that led to the discovery of Wolbachia  as intracellular
endosymbiotic bacteria of filarial nematodes. Their asso-
ciation with systemic inflammatory reactions to anti-filar-
ial chemotherapy and the possibility of exploiting these
bacteria as novel targets for antibiotic therapy of filariasis
were also discussed.
Main Issues
In Central and West Africa, particularly in central-south-
ern Cameroon, where onchocerciasis co-exists with L. loa,
severe adverse reactions involving inflammatory encepha-
lopathy and the presence of L. loa microfilariae in the CSF
have been observed following ivermectin therapy. These
observations prompted an examination of L. loa worms
for the presence of Wolbachia. Previous studies using elec-
tron microscopy have failed to detect endosymbionts.
Results from current studies using immuno-electronFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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microscopy show bacterial structures within host vacuoles
labeled with antibodies to Wolbachia surface proteins in
samples of infective larvae from Cameroon. Further, in
PCR-based studies on adult worms, microfilariae and
infective larvae have all been positive for the presence of
Wolbachia DNA, with unique sequences. Of note, 10% of
CSF samples from fatal cases of L. loa encephalopathy fol-
lowing treatment with Mectizan® were PCR-positive for
Wolbachia but DNA sequencing demonstrated that these
Wolbachia were derived from O. volvulus and not L. loa.
Cumulative results from these studies suggest that L. loa
does harbor Wolbachia endosymbionts, albeit in very low
numbers. Trials currently underway, in onchocerciasis
and lymphatic filariasis patients and those planned in loi-
asis patients, are designed to determine whether antibiotic
therapy can lead to adulticidal activity and long-term ste-
rility of the adult worms.
Discussion
• Presence of Wolbachia in L. loa is uncertain, evidence
from studies conducted by the Liverpool group indicates
that they are present, but other laboratories have not
obtained similar results.
• In its present form, antibiotic therapy is not suited to
mass treatment, since children and pregnant women can-
not receive doxycycline. Furthermore, the duration of
treatment required is not practical for mass treatment
programs.
Recommendations
1. Communicate with large pharmaceutical manufactur-
ers to access antibiotics that have been developed but are
not in general use and examine their effect on Wolbachia.
This strategy is considered to be more productive than
using antibiotics which are currently in use due to possi-
bility of resistance developing to pathogens other than the
target Wolbachia.
2. It would be informative to examine Wolbachia symbio-
sis in different strains of O. volvulus and L. loa.
3. Despite the controversy surrounding the presence of
Wolbachia in L. loa it may be useful to examine the poten-
tial for using antibiotics for the treatment of loiasis given
their potential for limiting pathological inflammation
during routine therapy.
4. Continue studies aimed at reducing the period of anti-
biotic treatment.
Note: Additional analysis using immunohistochemistry
and PCR have failed to corroborate initial findings of Wol-
bachia symbiosis in Loa loa (Evidence against Wolbachia
symbiosis in Loa loa. McGarry et al., Filaria Journal 2003,
2:9 and Obligatory symbiotic Wolbachia endobacteria are
absent from Loa loa. Büttner et al., Filaria Journal 2003,
2:10). We now conclude that Loa loa is free of Wolbachia
symbiosis. It is therefore highly improbable that Wol-
bachia  contributes to the neurological consequences of
SAE following ivermectin treatment in individuals with
infections of L. loa unaccompanied by other filarial
species.
Onchocerciasis-Related SAEs – Kwablah Awadzi
Overview
With the exception of L. loa related SAEs, there have been
very few serious or severe reactions to Mectizan® therapy,
despite wide application of the drug for onchocerciasis
control. In addition, because of their limited effect on
microfilariae, the benzimidazoles such as albendazole
that are currently being widely applied for lymphatic
filariasis elimination in onchocerciasis endemic areas, do
not predispose patients to adverse events related to para-
site death. Therefore, the presentation concentrated
mainly on the onchocerciasis-related adverse events
which have been observed and recorded following ther-
apy with pre-Mectizan® drugs – DEC and suramin – which
are no longer employed as therapeutic agents in onchocer-
ciasis endemic areas.
Main Issues
• Provided a definition of SAEs as defined in the 1996
International Conference on Harmonization of Technical
Requirements for the Registration of Pharmaceuticals for
Human Use (ICH) guidelines for Good Clinical Practice.
• Provided a very useful definition of causality, based on
the WHO definition as follows:
 Not related
 Unlikely
 Possibly related
 Probably related
 Most probably related
• A very comprehensive account of SAEs which have been
observed following therapy with the various drugs consid-
ered was presented. Events for which information was
provided included:
 Mortality
¾
¾
¾
¾
¾
¾Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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 Collapse and therapeutic shock
 Severe Symptomatic Postural Hypotension (SSPH)
• An account of systemic reactions and the associated
drugs was provided. The organ systems in which systemic
reactions typically occur are dermatological, lymphatic,
gastrointestinal, pulmonary, musculoskeletal, neurologi-
cal and ocular.
The introduction of Mectizan® for the treatment and con-
trol of onchocerciasis has eliminated the use of either
DEC or suramin. Although Mectizan® is generally well tol-
erated in patients with high O. volvulus microfilariae den-
sities, the treatment of patients with intense L. loa
infections has resulted in a number of SAEs including an
acute encephalopathy that occasionally results in death.
The pathogenesis of the encephalopathy is not well
understood but does not appear to be related to the
onchocercal post-treatment reactions.
Recommendations
1. During training, all health staff should be taught how
to distinguish between reactions which are drug-patient
related and those reactions which relate to the death of
parasite following drug administration
2. Because Mazzotti reactions are relatively common there
is still a great need to further study the immuno-patho-
genesis of these reactions, with a view to more effective
management.
Risk Factors For SAEs
Analysis of reported cases of PLERM – Nana Twum-Danso
Overview
1. Analysis of reported PLERM cases is very limited due to
substantial amounts of missing and incomplete data. The
only risk factors for development of PLERM that have
been identified, with reasonable confidence, are the
following:
• Age between 45 and 59;
• First-time treatment with Mectizan®;
• High L. loa microfilarial load – mean post-treatment
level of 3600 mf/ml, which if extrapolated, is suggestive of
a mean pre-treatment level of approximately 36,000 mf/
ml.
2. Data were insufficient to determine the risk factors for
poor clinical outcome (death or permanent neurologic
sequelae once PLERM develops)
Recommendations
1. More complete and reliable demographic, clinical and
laboratory data needs to be collected for the rare enceph-
alopathic SAE cases that occur in the future (see above rec-
ommendation for the Loiasis Technical Advisor in
Cameroon).
2. An epidemiologist with expertise in clustering should
review the geographic distribution of cases in Cameroon
to investigate other potential risk factors (e.g. environ-
mental, dietary etc.).
Pharmacologic neurotoxicity – Geoffrey Edwards
Overview
1. Ivermectin, a lipophilic drug, does not normally cross
the blood-brain barrier in vertebrates due to the action of
the P-glycoprotein (PGP) efflux transporter.
2. Ivermectin is also a substrate of cytochrome P-450
(CYP) 3A4, which is widely distributed in humans and
expressed in the liver and intestine.
3. Thus, drug-drug interactions at the level of PGP and/or
CYP3A4, may increase the neurotoxicity of ivermectin.
4. Albendazole is a known substrate of CYP3A4 but it does
not appear to be a substrate for human PGP.
5. Many foods, drinks and traditional medicines contain
inhibitors of transport proteins such as PGP.
Discussion
1. The local foods, alcoholic brews, and the traditional
and allopathic medicines vary from one region to another
in Cameroon and may warrant further investigation as
possible co-factors in PLERM cases through inhibition of
PGP and CYP3A4.
2. Side effects noted in studies using high-dose ivermectin
are mydriasis, nausea, vomiting and weakness. No neuro-
toxicity has ever been observed in these studies. Thus, it is
unlikely that inhibition of PGP and possible increased
levels of ivermectin in the brain, could result in the same
clinical picture as has been observed in PLERM. Another
mechanism needs to be sought.
Recommendations
1. Generate list of competitors of PGP and CYP3A4 that
may be co-administered with Mectizan® in the field.
2. Determine if the local foods, brews, and traditional
medicines used in the region of Cameroon where the
encephalopathy cases appear to be clustered could be
potential substrates of PGP and CYP3A4 (see above
¾
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recommendation for the Loiasis Technical Advisor in
Cameroon).
Alcohol – Mamoun Homeida
Overview
Alcohol intake in conjunction with Mectizan® treatment
has been implicated as a possible cause of SAEs, including
encephalopathy in L. loa endemic areas. As alcohol con-
sumption is very common in all known L. loa endemic
areas, there is a need to study this matter, in order to make
a clear recommendation about the possible harmful inter-
action with Mectizan®. There are, however, two issues
which must be clarified:
(a) the possible interaction between ethanol and Mecti-
zan®  would refer to acute, high intake of alcoholic
beverages;
(b) there are a great variety of local alcoholic brews in the
communities concerned, with varying possible associated
toxic compounds.
Main Issues
An ongoing cross-over study in Sudan where males are
administered Mectizan® in a fasting state, with a sorghum-
based meal (high in carbohydrates) or with a standard
quantity of a local alcoholic brew, was briefly presented.
Absorption of Mectizan® was not found to be significantly
different between the 3 groups. Surprisingly, no ethanol
was found in the local alcoholic brews in this study; rather
they contained approximately 2% methanol and 11%
propanol.
Recommendations
1. Local patterns of alcohol brewing and consumption
and use of traditional medicines in the high-risk areas of
Cameroon should be determined (see above recommen-
dation for the Loiasis Technical Advisor in Cameroon).
2. Pending the outcome of the above study, a clear recom-
mendation about alcohol intake at the time of Mectizan®
administration in mass treatment programs should be for-
mulated by the Mectizan® Expert Committee (MEC) and
communicated to field programs.
Risk-Management Approaches To L. Loa 
Associated SAEs
Risk group identification approach – David Addiss
Overview
1. A decision analysis model for mass treatment strategies
of onchocerciasis with Mectizan® in L. loa endemic areas
was presented (see Additional File 7 for current MEC rec-
ommendations for treatment strategies in areas co-
endemic for onchocerciasis and loiasis). The current
approach of village-by-village REA was compared with
RAPLOA alone, and RAPLOA in combination with REA.
Two thresholds of prevalence of high intensity L. loa
microfilaremia (20% and 40%) were illustrated.
2. Based on the preliminary assumptions in the model,
excluding communities at high risk of L. loa encephalop-
athy using RAPLOA techniques, did not appear to
decrease the expected cases of death or permanent neuro-
logic sequelae following the encephalopathic event.
3. The current version of the model focused on the risks
and benefits of Mectizan®  treatment, training, surveil-
lance, and supportive care for any SAEs that may occur.
4. Cost and feasibility factors have not yet been included
in the model.
Recommendations
1. Refine the estimates used in developing model
assumptions.
2. Work should continue on the model to include feasibil-
ity and cost of different strategies using REA, RAPLOA and
their combinations; different thresholds of RAPLOA
should be explored.
3. Consider the cost implications in carrying out effective
treatment in communities that are hypo-endemic for
onchocerciasis that will involve training of health staff,
sensitization and education of the communities as well as
monitoring and case management.
4. Develop the model further to allow its application to LF
particularly a risk benefit analysis.
Pre-treatment with albendazole – John Horton & Mark 
Bradley
Overview
The presentation provided overviews of evidence of the
effect that albendazole has, in both single and multiple
dose regimens, on a wide variety of filarial species includ-
ing L. loa. From the information available concerning the
effect that albendazole has on L. loa microfilarial densi-
ties, a simple model of the effect of temporally spaced sin-
gle dose administration of albendazole on L. loa
microfilarial levels was presented.
Main issues
• In a number of different filarial infections, multiple and
at least in some cases, single doses of albendazole leads to
a reduction in mf counts
• The pattern of clearance is consistent with an effect on
the adult (either a moderate macrofilaricidal effect or an
effect on fertility/embryo production)Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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• The clearance is slow, and detection requires relatively
prolonged follow up. Mazzotti reactions are not reported.
• The single dose effect seen with L. loa can be utilized to
potentially prevent reactions, and is compatible with a
public health approach
Discussion
1. Although one case of non-fatal encephalopathy has
been observed following albendazole therapy, most stud-
ies conducted to date show that single dose albendazole
does not result in an increase of adverse events during the
treatment of patients with LF or loiasis.
2. Effects of albendazole are slow to manifest: Wuchereria
bancrofti microfilarial densities decline to around 20% of
pre-treatment levels in LF patients over an 8–9 month
period. In loiasis patients the decline is less pronounced,
declining to around 50–70% of pre-treatment density
over a period of 6 months.
3. Observed patterns of microfilarial decay are consistent
with an effect on embryo-genesis rather than a direct effect
on the microfilariae
Recommendations
1. Research on the feasibility of albendazole as a pre-treat-
ment drug for Mectizan® in the onchocerciasis control and
LF elimination programs in L. loa endemic areas is
urgently needed. These studies should examine the effect
of temporally spaced dosing with single 400 mg and 800
mg dose albendazole in L. loa patients with high-risk mf
densities (> 30,000 mf/ml). A second intervention would
be administered after 2–3 months. The proposed studies
must show consistency of albendazole absorption.
Pre-treatment with low dose Mectizan® – Michel 
Boussinesq
Overview
In a recent study, the kinetics of decline in L. loa micro-
filaremia was no different for patients receiving a standard
dose of ivermectin than it was for those receiving a low
dose (3 mg).
Recommendation
Further research to identify a low dose of ivermectin that
could clear L. loa microfilaremia without provoking SAEs
should not be pursued further at this time since it does not
seem possible to identify a therapeutic minimum dose for
this effective microfilaricide.
Update On Management Of L. Loa 
Encephalopathy – Kenneth Brown
Overview
1. A limited amount of reliable information exists on L.
loa encephalopathy and its management, including treat-
ment guidelines by Gardon et al., reports of previous
workshops, and the published literature. However, this
information is not always readily available, especially out-
side Cameroon.
2. As no substantially new clinical data have been gener-
ated or published since the 1999 workshop in Tours, rec-
ommendations for clinical management have not
changed substantially.
Recommendations
1. Endorse the current L. loa encephalopathy treatment
manual by Gardon (Bull Liais doc OCEAC 1999; 32 pg
37-51), with modifications (i.e. no massage of coma
patients).
2. Corticosteriods are not recommended for treatment of
L. loa encephalopathy. (rationale: no evidence of efficacy
for this condition and they may be harmful)
3. Antihistamines are contraindicated for treatment of L.
loa encephalopathy. (rationale: no evidence of efficacy for
this condition and they sedate a patient with a neurologic
condition, interfering with diagnosis and neurologic
assessment)
4. Hydration is an important component of supportive
care. Hypotonic intravenous solutions should be avoided
if there is any evidence of increased intracranial pressure.
5. For village-level care, a simple algorithm card for recog-
nition, referral and care of L. loa encephalopathy should
be developed, pre-tested, and distributed.
6. Additional 'deliverables' for patient education, training
of medical personnel, establishment of best practices for
nursing and rehabilitation, counseling of patients and
families, and dissemination of treatment guidelines,
should be promulgated.
7. Efforts should be made to collect detailed clinical infor-
mation on every case of L. loa encephalopathy (see above
recommendation for Loiasis Technical Advisor in
Cameroon).
Health Educational Issues In Relation To SAEs – 
Nancy Haselow
Overview
1. The goal of Information, Education and Communica-
tion (IEC) strategies for Community-Directed TreatmentFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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with Invermectin (CDTI) in Cameroon has primarily been
that of increasing treatment coverage. In the past, IEC
activities have placed little emphasis on adverse events
(AEs), both mild and severe, even though recent surveys
have shown that both types of AEs affect treatment
coverage.
2. A "Vicious Cycle" between SAEs and low treatment cov-
erage was presented; fear of, and rumors about, SAEs
increase reticence of the population to take Mectizan® in
subsequent years which ultimately increases their risk of
SAEs that are associated with high L. loa microfilarial
loads since the microfilarial loads are increasingly
restored to pre-treatment levels with the passage of time.
3. Increased human and financial resources are required
to plan and implement CDTI in L. loa endemic areas due
to the need for enhanced IEC activities, increase in the
content and duration of training for CDDs and health
staff, additional supervision of community activities, and
provision of medical supplies to health facilities for man-
agement of any SAEs that may occur. In addition, because
of the need for strict monitoring of drug inventory and
close supervision of community activities, Mectizan® dis-
tribution in these areas by definition, does not and can
not, fit into the classic CDTI approach.
4. Great efforts have been made in the past year to include
Adverse Event (AE) occurrence, referral and management
in the IEC plans of mass treatment programs in
Cameroon.
5. There is a need for emphasis on community-based
research in the design of IEC tools with greater importance
placed on pre-testing these tools before producing them
en masse for the entire country. In addition, given the lin-
guistic, cultural and religious differences in the country,
IEC tools must be tailored for the specific audience.
6. Effective management of SAE cases, with early and
appropriate feedback to affected families and communi-
ties (including counseling), is a critical component of the
IEC strategy. This has not yet been fully employed.
Recommendations
1. Health education and communication materials
should be developed based on research carried out in the
communities. Subsequently, the product should be tested
and refined before widespread application.
2. Counseling methods need to be developed to support
those who suffer serious adverse event. Two aspects of
counseling should be considered:
(a) Medical counseling carried out by medical staff to
explain the condition to the affected family; and
(b) Social support that should be carried out by a promi-
nent person in the community. Regarding the latter it was
suggested that the religious leader would be apt to provide
such support.
3. Training materials need to be developed further to
enhance the efficiency at all levels. In this regard it was
also pointed out that selection of subjects from communi-
ties for carrying out REA is not always random. It is recom-
mended that training of health staff on this subject should
stress the importance of random selection of subjects to
give an accurate estimate of endemicity.
4. In order to encourage early management of SAEs, fam-
ilies should be educated to seek treatment as early as pos-
sible for even mild AEs. Cost should not be a barrier to
seeking medical care for AEs.
5. Appropriate information on adverse reactions to Mecti-
zan® treatment needs to be communicated to the commu-
nities to avoid development of reticence to continue
subsequent treatments.
Review Of Present Recommendations For 
Mectizan® Treatment In L. Loa Endemic Areas 
(See Additional File 7)
Recommendations
1. Introductory text needs to be updated to reflect knowl-
edge gained since 1999 including the new RAPLOA tech-
nique once it has been validated.
2. Recommendations for program areas where there has
been no previous treatment, or fewer than 2 rounds of
annual treatment, or less than 60% coverage during 2 or
more rounds of annual treatment, or have had cases of
encephalopathic SAEs following treatment, needs to be
reworded to reflect the following:
• recommended strategy should be made on a commu-
nity-by-community basis rather than for entire program
areas since there is often great variability in treatment cov-
erage within different communities in a given program
area.
• recommended strategy for communities found to be
hypo-endemic by REA, particularly if previously believed
to be hyper- or meso- endemic by REMO, should be made
more flexible.
3. Recommendations for follow-up care after clinic-based
treatment should be more clearly written.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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4. Consideration should be given to moving the section
on "the ultimate decision on how to proceed ... should be
made by the National Onchocerciasis Task Force (NOTF)
and the Ministry of Health" to the top of the guidelines so
that program managers more fully appreciate their role
and authority in implementing the recommendations.
The MEC and TCC (please see the Glossary of Abbrevia-
tions) should clarify whether the above-referenced recom-
mendations should be viewed as 'strict' recommendations
or 'flexible' guidelines.
Reporting Of SAEs – Amy Klion
Overview
The different and overlapping goals and responsibilities
of AE reporting were reviewed for different categories of
institutions and professionals (Food and Drug Adminis-
tration (FDA) of the U.S., manufacturer/distributor,
health professionals and clinical researchers).
The limitations of AE reporting were also presented:
Spontaneous reporting (FDA and similar agencies)
• AE recognition is subjective
• Underreporting is systemic
• Biases (length of time a product has been on the market,
country, quality of data) can affect reporting
• Estimation of population exposure is imprecise
Active surveillance (Research studies; Prescription-Event
Monitoring)
• Adverse event recognition is subjective
• Costly (in time and money)
Main issues
With regard to the MDP, the presumed goals of AE report-
ing are:
• to obtain information pertaining to the incidence,
pathogenesis and treatment of L. loa-related encephalopa-
thy following Mectizan® administration,
• to identify other severe adverse events that may lead to
decreased coverage.
The responsibility of the MDP with regards to AE report-
ing is the transmittal of SAE reports to manufacturer and/
or FDA. However, it faces numerous limitations:
• Quality and quantity of information,
• Logistics (information not available),
• Form (information not recorded),
• Variability in reporting,
• Subjective nature of adverse event recognition (percep-
tion of what is to be reported).
The possibilities for improvement of AE reporting of the
MDP are:
• Encourage reporting of severe or unexpected AEs instead
of "serious" AEs,
• Consider two-step form:
 Step 1: check box/short text form to collect research
data on all reported AEs
 Step 2: additional (free-text) information required by
FDA for reported SAEs,
• Institution of a "rapid response team" to augment and
standardize acute and follow-up information collected on
cases of L. loa-induced encephalopathy,
Recommendations
1. MDP needs to clearly define the reasons why SAE
reports are required and these messages must be conveyed
to health staff working in program areas
2. MDP needs to clearly differentiate between expected
reactions to therapy and what could constitute an unex-
pected event. This difference needs to be communicated
to health staff in program areas. It is anticipated that this
understanding should reduce the number of reports for
expected events.
3. The current SAE reporting form may be too complex
and therefore it is not being adequately completed with
subsequent loss of vital information. It is recommended
that the form is examined and possible revised. The alter-
native is to have a 2-step reporting system as suggested
above.
4. The MDP should examine its current database and com-
pile a list of data which need to be captured to better
understand and track the occurrence of L. loa related
encephalopathic events following Mectizan® treatment.
Feedback on the SAE reporting survey that the MDP is
conducting will be available in July 2002. It is hoped that
this will provide useful input for the re-design of the SAE
¾
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form to make it better suited for field use. After July, a data
capture tool should be prepared which will be adminis-
tered by a technical support person based in Cameroon
(see above recommendation for Loiasis Technical Advisor
in Cameroon).
Other Matters
Global Programme to Eliminate Lymphatic Filariasis 
(GPELF)
Discussion
The importance and urgency of addressing safety issues
related to treatment in areas of onchocerciasis and/or LF
co-endemicity with L. loa was stressed. Various potential
Table 1: Recommended Action Items
ACTION ITEM RELATIVE COST RELATIVE IMPORTANCE
1. Mapping
Updating country maps High/Moderate High
RAPLOA implementation Low High
2. Pathogenesis and Clinical Aspects
Field case studies
Serial sampling (blood, CSF) Moderate High
Quick response (telephone system) Moderate High
Better clinical definition Low High
Improve data forms etc. Low High
Analysis of evolution of clinical picture to identify potential early warning signs Low High
Research on HPCs
Pathological specimens (with blood/serological correlates) Moderate High
Utility as early warning sign for PLERM Moderate High
Reliability of application by CDDs & community health workers Low High
Support Local Loiasis Technical Advisor High High
Hospital studies (more sophisticated sampling/testing) Moderate High
Population studies
Mdr1 and other genetic studies High Low
Food and alcohol toxicity surveys Moderate Moderate
Post-mortem studies
Core samples Low High
Immunohistology etc on AFIP/Marc Wéry samples Low High
Conjunctival samples Moderate Moderate
3. Epidemiologic Aspects
Use of GIS software to map SAE cases Low High
Support epidemiologist specialized in cluster phenomena High High
Research on RAPLOA techniques applied at individual level Low High
4. Pre-Treatment Approaches for L. loa endemic areas
Explore existing drugs with potential efficacy against L. loa Moderate High
Albendazole – repeated doses Moderate Moderate
Wolbachia (follow developments and respond where appropriate) (Low) (High)
Steroids (hospital study) Moderate Moderate
List of co-substrates for PGP and CYP3A4 potentially used locally Low Moderate
5. Animal Models
Primates in Cameroon
To eventually lead to new therapies High (Pending))
To study pathogenesis High Low
Mouse (should be secondary to primate studies) Moderate (Controversial)
Dog (unlikely to be comparable) High Low
In vitro studies (already being done at NIH) (High) (Medium)
6. SAE management improvement / best care methodology
Improve SAE surveillance & reporting system Low High
Validation of activities, training, surveillance system Low High
Development & assessment of risk management models (incl. for LF) Low High
Education & counseling materials guided by community-based research Low High
Simple algorithm card for recognition, referral & management Low High
7. Support research addressing expansion of programs to LF areas Low HighFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S2
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treatment strategies using Mectizan® alone, pre-treatment
with albendazole followed by Mectizan®, and pre-treat-
ment with Mectizan®  followed by albendazole were
discussed.
Recommendations
1. Well-designed research studies need to be conducted to
address, as much as possible, safety issues in relation to
combination treatment regimens with Mectizan®  and
albendazole in areas where LF is co-endemic with loiasis.
2. The relevant technical bodies that oversee these issues
(TDR, MECAC, TAG, RPRG for AFRO - please see the Glos-
sary of Abbreviations) should coordinate their input into
this issue.
Conclusions & Recommendations
In addition to the conclusions and recommendations for-
mulated under each section of this report, an overview of
the plan of action and follow-up for future work, high-
lighting the cost and relative importance of each recom-
mendation was agreed upon and is presented in Table 1.
Closure
The meeting closed at 1800 hours on 30 May. The partici-
pants expressed their appreciation to Merck and GSK for
sponsoring the meeting, to Professor Mamoun Homeida
for chairing the meeting, and to Professor David
Molyneux and his team for hosting the meeting and for
making such pleasant and practical arrangements for the
working group.
Glossary of Abbreviations
AE Adverse Experience/Event
AFIP US Armed Forces Institute of Pathology
CDC US Centers for Disease Control and Prevention
CDD Community Drug Distributor
CDTI Community-Directed Treatment with Ivermectin
CMFL Community Microfilarial Load
CNS Central Nervous System
CSF Cerebrospinal Fluid
CYP Cytochrome P450
DEC Diethlycarbamazine
FDA US Food and Drug Administration
HKI Hellen Keller International
HPC Hemorrhages of the Palpebral Conjunctiva
IEC Information, Education & Communication
MDP Mectizan® Donation Program
mdr1 gene that encodes the Multiple Drug Resistance
Associated Protein in humans
MEC Mectizan® Expert Committee
MECAC Mectizan®  Expert Committee/Albendazole
Coordination
NIH US National Institutes of Health
NOTF National Onchocerciasis Task Force
PCR Polymerase Chain Reaction
PGP p-Glycoprotein
PLERM Probable/Possible Loa loa Encephalopathy tempo-
rally Related to treatment with Mectizan®
RAPLOA Rapid Assessment Procedure for Loiasis based
on restricted definition of history of eye worm passage
REA Rapid Epidemiologic Assessment (of onchocerciasis)
REMO Rapid Epidemiologic Mapping of Onchocerciasis
RPRG Regional Programme Review Group (for the Elimi-
nation of Lymphatic Filariasis)
SAE Serious Adverse Experience/Event
SSI Sight Savers International
SSPH Severe Symptomatic Postural Hypotension
TAG Technical Advisory Group (for the Global Pro-
gramme to Eliminate Lymphatic Filariasis)
TDR UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases
TCC Technical Consultative Committee for the African
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